by Ethan A. Huff, staff writer

(NaturalNews) Current government recommendations of 400 or 600 international units (IU) of vitamin D a day are insufficient to prevent serious diseases like breast cancer, a new study published in the journalAnticancer Researchhas found. Researchers from the University of California, San Diego (UCSD) School of Medicine and Creighton University (CU) School of Medicine discovered that when much higher doses of vitamin D are taken daily, the risks associated with developing several major diseases are reduced by about half.

“We found that daily intakes of vitamin D by adults in the range of 4000-8000 IU are needed to maintain blood levels of vitamin D metabolites in the range needed to reduce by about half the risk of several diseases — breast cancer, colon cancer, multiple sclerosis, and type 1 diabetes,” said Cedric Garland, DrPH, professor of family and preventive medicine at the UCSD Moores Cancer Center.

Read the Full Article Here: http://www.naturalnews.com/031613_vitamin_D_breast_cancer.html

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.